US FDA Moves To Codify Size-Based Threshold For Drugs To Be Deemed Biologics
Executive Summary
Agency proposes to define by regulation which proteins previously approved as drugs will be deemed licensed biologics, and therefore potentially subject to biosimilars competition. Industry has opposed the size-based thresholds, preferring a structure-based approach.
You may also be interested in...
Mylan And Biocon's Insulin May Get US Reprieve
Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.
Mylan/Biocon’s Insulin Glargine Would Get A Respite Under US Budget Legislation
Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.
Insulin Application Reviews Would Continue After March 2020 Under Senate Bill
Bill would change US FDA's approach to handling follow-on applications submitted under Section 505 once products become "deemed" as biologics 23 March 2020, and could amend a provision in the Senate HELP Committee's health care bill, which aligns with FDA policy.